Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide (Q35547376)

8 August 2017

title

Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide (English)

1 reference

8 August 2017

1 reference

5

Khamashta MA

1 reference

8 August 2017

6

Hughes GR

1 reference

8 August 2017

Martin-Suarez I

1

1 reference

8 August 2017

D'Cruz D

series ordinal

2

1 reference

8 August 2017

Mansoor M

series ordinal

3

1 reference

8 August 2017

Fernandes AP

series ordinal

4

1 reference

8 August 2017

language of work or name

English

0 references

publication date

1 August 1997

1 reference

Annals of the Rheumatic Diseases

8 August 2017

published in

1 reference

8 August 2017

volume

56

1 reference

8 August 2017

issue

8

1 reference

8 August 2017

page(s)

481-487

1 reference

The 1982 revised criteria for the classification of systemic lupus erythematosus

8 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1752422

Wegener's Granulomatosis: Prospective Clinical and Therapeutic Experience With 85 Patients for 21 Years

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1752422

Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1752422

Wegener's granulomatosis: studies in eighteen patients and a review of the literature

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1752422

NIH conference. Lupus nephritis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1752422

Cyclophosphamide-induced bladder toxicity in wegener's granulomatosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1752422

Cytotoxic drugs: their clinical application to the rheumatic diseases

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1752422

Short course of weekly low-dose intravenous pulse cyclophosphamide in the treatment of lupus nephritis: a preliminary study

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1752422

Short term effects of intravenous pulses of cyclophosphamide in the treatment of connective tissue disease crisis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1752422

Drug eruptions from mesna. After cyclophosphamide treatment of patients with systemic lupus erythematosus and dermatomyositis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1752422

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1752422

Response of cyclophosphamide-resistant Wegener's granulomatosis to etoposide

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1752422

Cyclophosphamide Therapy of Severe Systemic Necrotizing Vasculitis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1752422

Wegener Granulomatosis: An Analysis of 158 Patients

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1752422

The Use of Alkylating Agents in the Treatment of Wegener's Granulomatosis

26 September 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/9306871

12 December 2020

Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis)

1 reference

https://pubmed.ncbi.nlm.nih.gov/9306871

12 December 2020

Suppression of human B lymphocyte function by cyclophosphamide

1 reference

https://pubmed.ncbi.nlm.nih.gov/9306871

12 December 2020

Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/9306871

12 December 2020

Effect of treatment on the evolution of renal abnormalities in lupus nephritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/9306871

12 December 2020

Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/9306871

12 December 2020

Enzyme immunoassays for the detection of IgG and IgM anti-dsDNA antibodies: clinical significance and specificity

1 reference

https://pubmed.ncbi.nlm.nih.gov/9306871

12 December 2020

Cyclophosphamide in severe polymyositis

1 reference

https://pubmed.ncbi.nlm.nih.gov/9306871

12 December 2020

The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction

1 reference

https://pubmed.ncbi.nlm.nih.gov/9306871

12 December 2020

Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only

1 reference

https://pubmed.ncbi.nlm.nih.gov/9306871

12 December 2020

Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/9306871

12 December 2020

New York University/Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: efficacy in steroid unresponsive lupus nephritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/9306871

12 December 2020

Identifiers

DOI

10.1136/ARD.56.8.481

1 reference

release_zd52z67cnjbgrmybgeas6wt57q

8 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zd52z67cnjbgrmybgeas6wt57q

24 November 2022

mapped directly with Wikidata item

PMC publication ID

1752422

1 reference

8 August 2017

1 reference